Reaction
Choroidal Neovascularisation reporting signals
As of the last recalculation, Choroidal Neovascularisation appears in 837 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 585.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 358 | 585.2 | 593.3 |
| Aflibercept | 86 | 76.3 | 76.5 |
| Faricimab | 16 | 50.0 | 50.1 |
| Bevacizumab | 67 | 14.5 | 14.5 |
| Polatuzumab Vedotin | 3 | 7.7 | 7.7 |